MADISON, Wis.–Promega Corporation announces the availability of the new pmirGLO Dual-Luciferase miRNA Target Expression Vector. pmirGLO supports both breadth and depth in the microRNA study. Researchers have both ability to measure a wide dynamic range of miRNA activity in a vast number of cell types and the option to create a stable cell line from one genetic construct for further research. More specifically, pmirGLO uses optimized firefly luciferase gene as the readout for activity, while also offering a Renilla luciferase/neomycin resistance gene for data normalization.

The pmirGLO vector allows a luciferase reporter gene assay to measure the function of endogenous or exogenous micro RNAs (miRNA). This vector also enables functional studies of sequence variations found in 3’-untranslated regions of genes often related to miRNA binding sites or other modulators of transcript stability. These elements are cloned into the pmirGLO vector to create a transcriptional fusion to firefly luciferase, allowing quantitative results with a simple and sensitive assay. This vector is the most recent addition to a collection of nearly 50 luciferase reporter vectors offered by Promega.

For more information, visit www.promega.com.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.